Neurogene
NGNE
96 hedge funds and large institutions have $342M invested in Neurogene in 2026 Q1 according to their latest regulatory filings, with 19 funds opening new positions, 43 increasing their positions, 16 reducing their positions, and 14 closing their positions.
308% more call options, than puts
Call options by funds: $3.4M | Put options by funds: $833K
169% more repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 16
36% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 14
3% more funds holding
Funds holding: 93 → 96 (+3)
2.39% more ownership
Funds ownership: 106.56% → 108.96% (+2.4%)
0% more capital invested
Capital invested by funds: $340M → $342M (+$1.62M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$4.89M |
| 2 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$2.91M |
| 3 |
Millennium Management
New York
|
+$2.59M |
| 4 |
CC
Casdin Capital
New York
|
+$2.42M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
+$2.13M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LGM
Logos Global Management
San Francisco,
California
|
-$4.02M |
| 2 |
Morgan Stanley
New York
|
-$1.66M |
| 3 |
Goldman Sachs
New York
|
-$1.05M |
| 4 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
-$1.02M |
| 5 |
TI
Trexquant Investment
Stamford,
Connecticut
|
-$892K |
NGNE Hedge Fund Activity: Q1 2026 in Review
96 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Neurogene (NGNE) for Q1 2026, worth a combined $342M — up 0.48% from $340M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new NGNE positions and 14 closed out — a net gain of 5 holders — while 43 added to existing stakes and 16 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $4.89M. The largest seller was Logos Global Management, exiting entirely with an estimated $4.02M sold.
- 96 institutional investors held Neurogene (NGNE) as of Q1 2026, up from 93 in Q4 2025.
- Funds reported $342M of Neurogene stock for Q1 2026, up 0.48% quarter-over-quarter.
- 19 funds opened new Neurogene positions in Q1 2026 and 14 closed out, a net change of +5 holders.
- The largest Neurogene buyer in Q1 2026 was Fidelity Investments, an estimated $4.89M added.
- The largest Neurogene seller in Q1 2026 was Logos Global Management, an estimated $4.02M sold.
Based on aggregated 13F filings for Q1 2026.